Clinical and Immunological Analysis of Cutaneous Leishmaniasis before and after Different Treatments

Table 3

Evolution of lesions in patients (𝑛=32) with cutaneous leishmaniasis secondary infections.

Evolution of lesions after treatments, 𝑛 = patients, 𝑛/32 = (%)
New lesion			Relapses
Patients	Doses	Remission, weeks	Patients	Doses	Remission, weeks
SR^a 4 (12.5)	None	8.50±3.41	3 (9.37)	None	4.7±3.0
			1 (3.12)	10, Glu^b	10
Glu^b 7 (21.87)	27.4±16.1	8.71±2.49	4 (12.5)	None	6.33±1.52
			3 (9.37)	25±10, Glu^b	6.5±3.79

aSR: spontaneous remission. bGlu: meglumine antimoniate or Glucantime.